Literature DB >> 30020542

Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis.

Hyunjin Kim1, Young-Min Lim1, Eun-Jae Lee1, Yeo Jin Oh1, Kwang-Kuk Kim1.   

Abstract

INTRODUCTION: Although thymectomy is an important therapeutic option for myasthenia gravis (MG), factors predicting remission after thymectomy are not well known.
METHODS: We retrospectively reviewed patients with acetylcholine receptor antibody (AChR-Ab)-positive MG who had undergone thymectomy. Prognostic factors predicting remission were investigated. Changes in AChR-Ab titer before and after thymectomy were also evaluated.
RESULTS: Among the 179 patients, 52.5% achieved complete stable or pharmacologic remission. Nonthymomatous pathology and mild preoperative status were favorable predictors of remission. The decrease in AChR-Ab titer after thymectomy was significant in nonthymomatous MG but not in thymomatous MG. DISCUSSION: Nonthymomatous pathology and mild preoperative status are prognostic factors that may predict remission after thymectomy. The decrease in AChR-Ab titer after thymectomy was significant in nonthymomatous MG but not in thymomatous MG, suggesting that the pathogenic role of the thymus differs according to pathology. Muscle Nerve 58:796-800, 2018.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  acetylcholine receptor antibody; myasthenia gravis; prognostic factors; thymectomy; thymic pathology; thymoma

Mesh:

Substances:

Year:  2018        PMID: 30020542     DOI: 10.1002/mus.26300

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

Review 1.  Thymectomy in Myasthenia Gravis: A Narrative Review.

Authors:  Danah Aljaafari; Noman Ishaque
Journal:  Saudi J Med Med Sci       Date:  2022-04-29

2.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

3.  Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.

Authors:  Ying Zhang; Fujun Li; Hongwen Zhu; Hongmei Yu; Tian Wang; Xudong Yan
Journal:  Neurol Sci       Date:  2022-01-18       Impact factor: 3.307

4.  Factors affecting minimal manifestation status induction in myasthenia gravis.

Authors:  Yi Li; Shumei Yang; Xiaohua Dong; Zhibin Li; Yuyao Peng; Wanlin Jin; Di Chen; Ran Zhou; Fei Jiang; Chengkai Yan; Huan Yang
Journal:  Ther Adv Neurol Disord       Date:  2022-03-29       Impact factor: 6.570

Review 5.  Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.

Authors:  Miriam L Fichtner; Ruoyi Jiang; Aoibh Bourke; Richard J Nowak; Kevin C O'Connor
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

6.  Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.

Authors:  Anna De Rosa; Marco Fornili; Michelangelo Maestri Tassoni; Melania Guida; Laura Baglietto; Loredana Petrucci; Antonio Chella; Franca Melfi; Marco Lucchi; Roberta Ricciardi
Journal:  Thorac Cancer       Date:  2020-11-03       Impact factor: 3.500

7.  No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.

Authors:  Lulu Wang; Shumin Wang; Haonan Yang; Jiaojiao Han; Xue Zhao; Sensen Han; Yingna Zhang; Jie Lv; Jing Zhang; Mingqiang Li; Ying Ji; Shuxian Zhou; Xiaoxiao He; Hua Fang; Junhong Yang; Yunke Zhang; Qingyong Zhang; Peiyang Gao; Feng Gao
Journal:  Brain Behav       Date:  2021-06-02       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.